While US biosimilar approvals have been thin on the ground in 2021 – with products delayed due to the FDA’s inability to conduct certain facility inspections during the COVID-19 pandemic – the market has nevertheless seen several firsts this year, including two interchangeability designations and the first ophthalmic biosimilar approval.

HHS agencies look to build on COVID-19 experience by developing quicker public/private responses to pandemics and supply chain threats.

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Federal agency seeks dialogue with industry on how to enable surge capacity for pandemic vaccines without cutting back on other production.One key factor: workforce development.